Showcasing WHO’s mRNA Vaccine R&D Priorities & Requirements for Low- & Middle- Income Countries

Time: 3:30 pm
day: Day 2 PM


• Numerous LMICs are acquiring mRNA vaccine production capacity as a tool to enable rapid response to future regional or global outbreaks. Maintaining this infrastructure requires that countries develop and manufacture mRNA vaccines for routine targets

• WHO, MPP, and their partners are building research networks to help these countries undertake R&D for mRNA vaccines against priority diseases in LMIC countries

• Reviewing the technical feasibility (PTRS) of developing the vaccines against these diseases, and also the probability that such vaccines would be procured (probability of policy development and procurement). This is a framework for R&D prioritisation to support these regions